NewsBenzingaFractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance Benzinga 2026.10.22 11:07 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181 Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $870 Dow Warns High Interest Rates and Weak Consumer Confidence Are Hurting Housing Demand Evercore ISI Group Maintains Outperform on Knight-Swift, Raises Price Target to $79 Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75 Stock of the Day: Where is the Bottom for AT&T?
Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181
Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75
